37 results about "Focal segmental glomerulosclerosis" patented technology

Disclosed are single nucleotide polymorphisms (SNIps) associated with breast cancer, lung cancer, prostate cancer, non-insulin dependent diabetes, end stage renal disease due to non-insulin dependent diabetes, hypertension, end stage renal disease F due to hypertension, myocardial infarction, colon cancer, hypertension, atherosclerotic peripheral vascular disease due to hypertension, cerebrovascular accident due to hypertension, cataracts due to hypertension, cardiomyopathy with hypertension, myocardial infarction due to hypertension, non-insulin dependent diabetes mellitus, atherosclerotic peripheral vascular disease due to non-insulin dependent diabetes mellitus, cerebrovascular accident due to non-insulin dependent diabetes mellitus, ischemic cardiomyopathy, ischemic cardiomyopathy with non-insulin dependent diabetes mellitus, myocardial infarction due to non-insulin dependent diabetes mellitus, atrial fibrillations without valvular disease, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease. cholecystectomy, degenerative joint disease, end stage renal disease and frequent de-clots, end stage renal disease due to focal segmental glomerular sclerosis, end stage renal disease due to insulin dependent diabetes mellitus, or seizure disorder. Also disclosed are methods for using SNPs to determine susceptibility to these diseases; nucleotide sequences containing SNPs; kits for determining the presence of SNPs; and methods of treatment or prophylaxis based on the presence of SNPs.

Focal and segmental glomerulosclerosis (FSGS) is a kidney disorder of unknown etiology and up to 20% of patients on dialysis have this diagnosis. A large family with hereditary FSGS carries a missense mutation in the TRPC6 gene on chromosome 11q, encoding the ion channel protein Transient Receptor Potential Cation Channel 6. The missense mutation is a P112Q substitution, which occurs in a highly conserved region of the protein, enhances TRPC6-mediated calcium signals in response to agonists such as angiotensin II, and alters the intracellular distribution of TRPC6 protein. Previous work has emphasized the importance of cytoskeletal and structural proteins in proteinuric kidney diseases. Our findings suggest a novel mechanism for glomerular disease pathogenesis.

The invention relates to methods, compositions, and kits for the treatment of proteinuria and / or hypertension (e.g., proteinuria and / or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and / or epleronone).

The invention relates to a protein marker of focal segmental glomerulosclerosis, and more specifically relates to an application of a connecting part selectively connected to one or more proteins in preparing a diagnostic reagent in a development process of human focal segmental glomerulosclerosis. The one or more proteins are selected from [alpha]1 antiprotease, alpha albumin, serum albumin, beta-2-microglobulin, ceruloplasmin, fetuin-B, kininogen, serum transferrin, carboxylesterase, immune globulin gamma-2A chain C region, plasminogen, lysosomal acid phosphatase, protein YIPF3, zinc [alpha]2 glycoprotein, alpha-2-HS-glycoprotein, protein AMBP or T cell immune globulin. Specifically, the invention relates to the application of a urine protein potential marker of human focal segmental glomerulosclerosis obtained by a rat model and mass spectrometry.

Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with Trypanosoma infection, e.g., by detecting at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with T. brucei. The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and / or a deletion of N388 and Y389 to the subject.

This invention provides organic biomolecule markers (e.g., proteins) useful for differentiating minimal change nephrotic syndrome (MCNS) from focal segmental glomerulosclerosis (FCS), membranous nephrothropy (MN), and membranoproliferative glomerulonephritis (MPGN). This invention also provides organic biomolecule markers useful for evaluating the therapeutic value of agents for treating kidney disease.

The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage / lymphocyte infiltration in the kidney, etc.

The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

The invention discloses application of reagent of markers for detecting focal segmental glomerulosclerosis (FSGS) to preparation of a kit for diagnosing and predicating focal segmental glomerulosclerosis, the focal segmental glomerulosclerosis markers are one or more of miR-17, miR-451, miR-106a and miR-19B, By means of the markers for diagnosing and predicating focal segmental glomerulosclerosis, new blood markers are provided for clinical diagnosis of focal segmental glomerulosclerosis, peripheral blood testing can be directly conducted, and the markers have the advantages of being good in specificity and high in sensitivity, have good clinical diagnosis value and lay a foundation for implementation of hematology diagnosis of FSGS.

The invention provides a novel purpose of a microRNA-30 family, and concretely to an application of the family used as a podocyte injury marker for patients with focal segmental glomerulosclerosis (FSGS). In addition, the invention further provides an application of the microRNA-30 family in preparation of medicaments for treating the podocyte injury. According to the invention, the microRNA-30 family facilitates diagnosis for the patients with the focal segmental glomerulosclerosis (FSGS) and the preparation of the medicaments for treating the podocyte injury, and thus has an extremely important significance for diagnosis and treatment of chronic kidney diseases.

The invention discloses a use of capparis spinosa in preparing drugs for treating kidney diseases, in particular to an application in preparing drugs for treating focal segmental glomerulus sclerosis. The invention explains the action mechanism of the medicine through the therapeutic effects of capparis spinosa on the focal segmental glomerulus sclerosis of rat models and the initial screening of gene chips, and shows remarkable curative effect on kidney diseases through the clinical experiment of the medicine prepared by capparis spinosa, in which no side effects as bone marrow suppression, liver damage and so on are found, thus being proved to have a broad application prospect.

The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and / or treatment of kidney diseases and conditions. In one embodiment of the invention, the compounds and compositions of the invention improve kidney function by reducing formation of kidney cysts, reducing glomerule dilatation, reducing renal cell apoptosis and preventing increases in blood urea nitrogen. In another embodiment of the invention, the compounds and compositions of the invention may be used in the methods to prevent and / or treat acute kidney injury (AKI), chronic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, nephrotic syndrome, renal fibrosis and kidney cancer.

Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and / or an endothelin receptor inhibitor. The CCR2 antagonist may have the structure of formula (I).

Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with Trypanosoma infection, e.g., by detecting at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with T. brucei. The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and / or a deletion of N388 and Y389 to the subject.

The present invention provides methods for treating glomerulosclerosis such as focal segmental glomerulosclerosis (FSGS) or glomerulonephritis such as immunoglobulin A nephropathy (IgAN) by cyclohexenone compounds.

The invention relates to methods, compositions, and kits for the treatment of proteinuria and / or hypertension (e.g., proteinuria and / or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and / or epleronone).

Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and / or an endothelin receptor inhibitor.

Tetrahydronaphthyridines of formulaare disclosed. These compounds selectively inhibit αVβ3 without activating the αVβ3 receptor. They are useful for treating osteoporosis, acute myelogenous leukemia, sickle cell disease, focal segmental glomerulosclerosis, fibrosis, supravalvular aortic stenosis associated with Williams syndrome, tumors expressing αVβ3, tumor metastasis, bone resorption, T-cell lymphoma, retinal disease, age-related macular degeneration, diabetic retinitis, and herpes simplex virus infection. They may also be used for inhibiting tumor angiogenesis.

The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage / lymphocyte infiltration in the kidney, etc.

This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.

The invention discloses a mangosteen, in particular to new application of alpha-mangostin to an aspect of preparing medicines for treating focal segmental glomerulosclerosis. The alpha-mangostin extracted from mangosteen shells can obviously reduce the glomerulus and renal tubule fibrosis expression level, meanwhile, accelerates SIRT1 expression and inhibits NLRP3 expression, is obvious on effect of treating glomerulosclerosis, is higher in safety of clinical application, has no any side effects, and widens the path of treating the focal segmental glomerulosclerosis.

The present invention provides glomerulosclerosis markers for chronic glomerular diseases and detection kits of the glomerulosclerosis markers, and relates to the technical field of medicine. The glomerulosclerosis markers for the chronic glomerular diseases are miRNA-196a, miRNA-155, miRNA-490 and interleukin in urine, and the detection kits comprise a kit A and a kit B. An analysis proves that focal segmental glomerulosclerosis (FSGS) is more obvious in renal tubular interstitial injury than other glomerular diseases such as MN and MCD, compared with patients with chronic renal tubular interstitial lesions, interleukin in urine of patients with acute or chronic combined acute renal tubular interstitial lesions is obviously increased. Currently, in many renal tubular functional indexes widely adopted clinically at present, the interleukin in the urine can better reflect the acute renal tubular interstitial lesions, a basis is provided for early and specific clinical discovery of the renal tubular interstitial lesions, and early intervention and treatment of the tubular interstitial injury are one of important links for delaying progression of kidney diseases.

The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) remain poorly understood. A key question is how parietal epithelial cells (PECs) invade glomerular capillaries, thereby promoting injury and kidney failure. Here the inventors show that expression of the tetraspanin CD9 increases markedly in PECs in mouse models of CGN and FSGS, and in kidneys from individuals diagnosed with these diseases. Cd9 gene targeting in PECs prevents glomerular damage in CGN and FSGS mouse models. Mechanistically, CD9 deficiency prevents the oriented migration of PECs into the glomerular tuft and their acquisition of CD44 and β1 integrin expression. These findings highlight a critical role for de novo expression of CD9 as a common pathogenic switch driving the PEC phenotype in CGN and FSGS, while offering a potential therapeutic avenue to treat these conditions. Accordingly, CD9 represents a reliable biomarker and as well as a biotargets in glomerulonephritides.

Tetrahydronaphthyridines of formulaare disclosed. These compounds selectively inhibit αVβ3 without activating the αVβ3 receptor. They are useful for treating osteoporosis, acute myelogenous leukemia, sickle cell disease, focal segmental glomerulosclerosis, fibrosis, supravalvular aortic stenosis associated with Williams syndrome, tumors expressing αVβ3, tumor metastasis, bone resorption, T-cell lymphoma, retinal disease, age-related macular degeneration, diabetic retinitis, and herpes simplex virus infection. They may also be used for inhibiting tumor angiogenesis.

The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and / or treatment of kidney diseases and conditions. In one embodiment of the invention, said compounds and compositions of the invention improve kidney function by reducing formation of kidney cysts, reducing glomerule dilatation, reducing renal cell apoptosis and preventing increases in blood urea nitrogen. In another embodiment of the invention, compounds and compositions of the invention may be used in methods to prevent and / or treat acute kidney injury (AKI), chronic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, nephrotic syndrome, renal fibrosis and kidney cancer.

The invention discloses application of reagent of markers for detecting focal segmental glomerulosclerosis (FSGS) to preparation of a kit for diagnosing and predicating focal segmental glomerulosclerosis, the focal segmental glomerulosclerosis markers are one or more of miR-17, miR-451, miR-106a and miR-19B, By means of the markers for diagnosing and predicating focal segmental glomerulosclerosis, new blood markers are provided for clinical diagnosis of focal segmental glomerulosclerosis, peripheral blood testing can be directly conducted, and the markers have the advantages of being good in specificity and high in sensitivity, have good clinical diagnosis value and lay a foundation for implementation of hematology diagnosis of FSGS.

The invention provides novel application of a traditional Chinese medicine composition for treating podocytosis. Specifically, the composition consists of twelve traditional Chinese medicinal materials such as radix polygoni multiflori preparata, semen cuscutae, radix pseudostellariae, rhizoma atractylodis stir-fried with bran, fructus lycii, radix achyranthis bidentatae, herba lycopi, radix paeoniae rubra, poria cocos, rhizoma alismatis, semen plantaginis and cooked rhubarb, and is used for treating, preventing and relieving podocytosis such as nephrotic syndrome, focal segmental glomerulosclerosis and the like.